FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
GlobeNewswire
· *Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented..
